Literature DB >> 28576921

Novel "Elements" of Immune Suppression within the Tumor Microenvironment.

Devikala Gurusamy1,2, David Clever3, Robert Eil4, Nicholas P Restifo5,2.   

Abstract

Adaptive evolution has prompted immune cells to use a wide variety of inhibitory signals, many of which are usurped by tumor cells to evade immune surveillance. Although tumor immunologists often focus on genes and proteins as mediators of immune function, here we highlight two elements from the periodic table-oxygen and potassium-that suppress the immune system in previously unappreciated ways. While both are key to the maintenance of T-cell function and tissue homeostasis, they are exploited by tumors to suppress immuno-surveillance and promote metastatic spread. We discuss the temporal and spatial roles of these elements within the tumor microenvironment and explore possible therapeutic interventions for effective and promising anticancer therapies. Cancer Immunol Res; 5(6); 426-33. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28576921      PMCID: PMC5512605          DOI: 10.1158/2326-6066.CIR-17-0117

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  67 in total

Review 1.  Asthma.

Authors:  Christopher H Fanta
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 3.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

5.  Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.

Authors:  Shomik Sengupta; Christine M Lohse; Bradley C Leibovich; Igor Frank; R Houston Thompson; W Scott Webster; Horst Zincke; Michael L Blute; John C Cheville; Eugene D Kwon
Journal:  Cancer       Date:  2005-08-01       Impact factor: 6.860

Review 6.  Bronchiolitis.

Authors:  Rosalind L Smyth; Peter J M Openshaw
Journal:  Lancet       Date:  2006-07-22       Impact factor: 79.321

7.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

8.  Methionine inhibits autophagy and promotes growth by inducing the SAM-responsive methylation of PP2A.

Authors:  Benjamin M Sutter; Xi Wu; Sunil Laxman; Benjamin P Tu
Journal:  Cell       Date:  2013-07-18       Impact factor: 41.582

9.  Cardiac arrest due to hyperkalemia following therapy for acute lymphoblastic leukemia.

Authors:  D Wilson; A Stewart; J Szwed; L H Einhorn
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

10.  Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo.

Authors:  Mahesh Yadav; Cedric Louvet; Dan Davini; James M Gardner; Marc Martinez-Llordella; Samantha Bailey-Bucktrout; Bryan A Anthony; Francis M Sverdrup; Richard Head; Daniel J Kuster; Peter Ruminski; David Weiss; David Von Schack; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2012-09-10       Impact factor: 14.307

View more
  25 in total

Review 1.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

2.  PHA eludes macrophage suppression to activate CD8+ T cells.

Authors:  Yelizavet D Lomakova; Jennifer Londregan; Jeffrey Maslanka; Naomi Goldman; John Somerville; James E Riggs
Journal:  Immunobiology       Date:  2018-11-03       Impact factor: 3.144

3.  Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Authors:  Shilpak Chatterjee; Paramita Chakraborty; Anusara Daenthanasanmak; Supinya Iamsawat; Gabriela Andrejeva; Libia A Luevano; Melissa Wolf; Uday Baliga; Carsten Krieg; Craig C Beeson; Meenal Mehrotra; Elizabeth G Hill; Jeffery C Rathmell; Xue-Zhong Yu; Andrew S Kraft; Shikhar Mehrotra
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

4.  Initial In Vitro Development of a Potassium-Based Intra-Articular Injection for Osteoarthritis.

Authors:  Josh Erndt-Marino; Patricia Diaz-Rodriguez; Mariah S Hahn
Journal:  Tissue Eng Part A       Date:  2018-06-04       Impact factor: 3.845

5.  The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets.

Authors:  Mujeeb R Cheerathodi; David G Meckes
Journal:  Future Virol       Date:  2018-12-03       Impact factor: 1.831

6.  A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment.

Authors:  Ameet A Chimote; Andras Balajthy; Michael J Arnold; Hannah S Newton; Peter Hajdu; Julianne Qualtieri; Trisha Wise-Draper; Laura Conforti
Journal:  Sci Signal       Date:  2018-04-24       Impact factor: 8.192

7.  Default polyfunctional T helper 1 response to ample signal 1 alone.

Authors:  Luca Danelli; Georgina Cornish; Julia Merkenschlager; George Kassiotis
Journal:  Cell Mol Immunol       Date:  2020-04-20       Impact factor: 11.530

Review 8.  Accomplices of the Hypoxic Tumor Microenvironment Compromising Antitumor Immunity: Adenosine, Lactate, Acidosis, Vascular Endothelial Growth Factor, Potassium Ions, and Phosphatidylserine.

Authors:  Peter Vaupel; Gabriele Multhoff
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

Review 9.  Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.

Authors:  Ramazan Rezaei; Hadi Esmaeili Gouvarchin Ghaleh; Mahdieh Farzanehpour; Ruhollah Dorostkar; Reza Ranjbar; Masoumeh Bolandian; Majid Mirzaei Nodooshan; Akbar Ghorbani Alvanegh
Journal:  Cancer Gene Ther       Date:  2021-06-22       Impact factor: 5.854

10.  The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.

Authors:  Xiuli Wang; Christian Huynh; Ryan Urak; Lihong Weng; Miriam Walter; Laura Lim; Vibhuti Vyas; Wen-Chung Chang; Brenda Aguilar; Alfonso Brito; Aniee Sarkissian; N Achini Bandara; Lu Yang; Jinhui Wang; Xiwei Wu; Jianying Zhang; Saul J Priceman; Hong Qin; Larry W Kwak; Lihua E Budde; Sandra H Thomas; Mary C Clark; Leslie Popplewell; Tanya Siddiqi; Christine E Brown; Stephen J Forman
Journal:  Cancer Immunol Res       Date:  2020-10-22       Impact factor: 12.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.